NCT06900400 Sustained Endogenous Attention Deficits in Attention Deficit Hyperactivity Disorder
| NCT ID | NCT06900400 |
| Status | Recruiting |
| Phase | — |
| Sponsor | IRCCS Eugenio Medea |
| Condition | ADHD - Attention Deficit Disorder With Hyperactivity |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2024-11-11 |
| Primary Completion | 2026-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2024-11-11 with a primary completion date of 2026-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Subjects with ADHD may exhibit deficits in sustained internal attention. The "Sustained-Paced Finger Tapping" test was recently developed and experimentally used in international literature to assess sustained internal attention in typically developing children. This clinical study has several objectives: 1) to assess the presence of "internal" sustained attention deficits in children with ADHD through the "Sustained-Paced Finger Tapping"; 2) to evaluate the discriminant and ecological validity of the "Sustained-Paced Finger Tapping."
Eligibility Criteria
Inclusion Criteria: * ADHD Group (1) Subjects with a diagnosis of ADHD of any severity level and subtype * ADHD Group (2) "Medication-naive" ADHD subjects, meaning subjects who have not been prescribed and/or have not yet started any pharmacological treatment for ADHD * ADHD Group (3) IQ ≥ 70 * Non-ADHD Group, Normal IQ Exclusion Criteria: * for both groups, symptomatology suggestive of autism spectrum disorders, psychotic disorders, mood disorders, and anxiety disorders * for both groups, use of psychotropic drugs * for both groups, subjects with cerebral palsy and/or neuromotor and neuromuscular disorders * for both groups, CNS diseases, e.g., epilepsy and/or neurodegenerative diseases, or central nervous system injuries resulting from, for example, head trauma or stroke * for the non-ADHD group, presence of ADHD symptoms
Frequently Asked Questions
Who can join the NCT06900400 clinical trial?
This trial is open to participants of all sexes, aged 6 Years or older, up to 13 Years, studying ADHD - Attention Deficit Disorder With Hyperactivity. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06900400 currently recruiting?
Yes, NCT06900400 is actively recruiting participants. Visit ClinicalTrials.gov or contact IRCCS Eugenio Medea to inquire about joining.
Where is the NCT06900400 trial being conducted?
This trial is being conducted at Brindisi, Italy, Lecce, Italy.
Who is sponsoring the NCT06900400 clinical trial?
NCT06900400 is sponsored by IRCCS Eugenio Medea. The trial plans to enroll 50 participants.